JW Tx’s Relma-cel (JWCAR029; CD19 CAR-T) Approved in China as Benoda for ≥3L R/R LBCL
On Friday, September 3, the Chinese NMPA announced (press release) the approval of JW Therapeutic’s relma-cel (relmacabtagene autoleucel / JWCAR029; CD19 CAR-T) in ≥3L r/r LBCL. Of note, relma-cel will be commercialized under the brand name Benoda. Below, Celltelligence provides insights on potential reimbursement hurdles JW Tx may face in China, while discussing Kymriah’s (Novartis’s CD19 CAR-T) delayed Chinese approval.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.